Target intelligence / Profile preview

Chymotrypsin-like elastase family member 3B (CELA3B)

Target
CELA3B
Molecular classification
Enzyme, Serine protease, Peptidase S1 family, Elastase subfamily
01

Overview

Chymotrypsin-like elastase family member 3B (CELA3B) is a pancreatic enzyme and serine protease primarily expressed in the acinar cells of the pancreas and secreted as a zymogen into the intestine, where it acts to digest proteins, preferentially cleaving at alanine residues[1][3][7]. Unlike other elastases, CELA3B has little elastolytic activity but may participate in cholesterol transport and metabolism in the gut[1][5]. It is clinically significant as fecal elastase 1, a stable marker used for non-invasive assessment of exocrine pancreatic function, especially in the diagnosis of pancreatic insufficiency[6]. Mutations such as R90C can cause a gain of function by increasing translation and secretion of active protease, leading to increased risk of pancreatitis and other pancreatic pathologies, including familial forms involving diabetes and cancer[4]. Immunostaining for CELA3B is highly specific for pancreatic acinar cell carcinoma and rarely found in other tissues[2].

Other names
Elastase 3BELA3BProtease EProteinase EElastase IIIBElastase-3BPancreatic endopeptidase ECholesterol-binding pancreatic proteaseFecal elastase 1Pancreatic elastase 1CBPP
02

Mechanism of action

Serine protease inhibition (for theoretical or research elastase inhibitors). Any identified drug action would be by blocking the enzymatic activity of the active protease.

03

Biological functions

Protein digestion (preferential cleavage after alanine residues)Intestinal transport and metabolism of cholesterolPancreatic zymogen activation and digestive function in the intestine
04

Disease associations

Exocrine pancreatic insufficiencyChronic pancreatitisFamilial pancreatitis with diabetes and pancreatic cancer (in context of certain mutations)Potential marker for pancreatic diseases
05

Safety considerations

Overexpression or gain-of-function mutations can increase risk/severity of pancreatitis[4].Insufficient function (loss) associated with maldigestion, malabsorption, and related symptoms[1][6].
06

Interacting drugs

No approved drugs are specifically listed as direct inhibitors or activators of CELA3B. However, protease inhibitors targeting serine proteases (including research-use elastase inhibitors) may affect its function[4].
07

Biomarkers

Fecal elastase 1: clinical biomarker for pancreatic exocrine function and diagnosis of exocrine pancreatic insufficiency[6].CELA3B immunostaining as a marker for diagnosing pancreatic acinar cell carcinoma[2].

Beyond the preview

Go deeper on Chymotrypsin-like elastase family member 3B (CELA3B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chymotrypsin-like elastase family member 3B (CELA3B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call